PRESS RELEASE

Global Kratom Coalition Responds to 60 Minutes: Federal Regulators Drew a Clear Line. CBS Ignored It.

WASHINGTON, D.C, November 17th, 2026, FinanceWire


The Global Kratom Coalition issued the following statement in response to the November 15th 60 Minutes broadcast story about ‘kratom’.

Our hearts go out to the families who shared their experiences with 60 Minutes. We take their experiences seriously. However, selectively presenting information to support a one-way narrative is not responsible journalism.

Americans expect more from 60 Minutes. CBS News says it's dedicated to the “highest quality journalism under standards we pioneered and continue to set today.” Sunday’s broadcast did not meet that standard. It made sweeping claims about natural kratom leaf, a botanical used by 23 million Americans that neither the science nor the everyday experience of those consumers support. It took rare exceptions and stories and presented them as the norm. It did this without interviewing a single person who consumes natural kratom, or any of the leading US researchers running federally funded studies on natural kratom.

Instead, 60 Minutes turned to Dr. Andrew Kolodny, an addiction psychiatrist and paid mass tort expert, rather than scientists who have spent years directly studying kratom. His recent kratom publications are commentary, not original clinical trials or laboratory research on natural kratom leaf. They support only the narrative he sells to the media and mass-tort lawyers. While his opinions were presented as authoritative, the researchers who actually study the plant were left out entirely.

It reported a five-year cumulative death count without telling viewers that kratom’s share of overdose deaths has held steady and those numbers attribute mitragynine detections in deaths – not that kratom caused the deaths. And it blurred the line between natural kratom leaf and lab-made concentrated synthetics – the very distinction federal regulators have spent the past year drawing.

Viewers deserved better.

Washington has already drawn the line between natural kratom leaf and concentrated synthetic 7-OH and other novel derivatives.

On October 9, 2026, HHS recommended science-based thresholds to target dangerous lab-made products. HHS Secretary Robert F. Kennedy Jr. was explicit about what the agency did and why: “We are drawing a clear line between natural kratom and dangerous, enhanced opioid products.” He added: “We listened to the public, followed the science, and developed a clear recommended threshold for temporary scheduling that targets concentrated 7-OH and MGPI without sweeping natural botanical kratom into Schedule I.”

60 Minutes did not report this. The broadcast never explained what the threshold does, which products it captures, or why federal scientists drew the line where they did, and it did not interview anyone who could.

The Broadcast Left Out

Twenty-three million Americans consume natural kratom leaf. The broadcast did not include one of them. It did not include a single researcher who studies the plant. And it did not include the federal record that contradicts its central claim.

A Food and Drug Administration single-ascending-dose study of natural kratom leaf tested servings up to 12 grams — four times greater than the amount used by typical consumers — and found no concerning adverse effects and strong tolerability.

To date there have been 18 clinical trials conducted on natural kratom leaf, including one from FDA, in addition to hundreds of non-clinical studies. Further to this, there have been more than 1200 peer reviewed scientific papers published on natural kratom, most being published over the past decade.

Both HHS and DEA made it abundantly clear in their press releases: “These actions are not intended to regulate natural leaf kratom that does not contain enhanced levels of 7-OH.”

CBS’s claims of a blanket twentyfold increase does not hold up against actual notices. The concentration ceiling did double from 0.05% to 0.1%, which in absolute terms is still a minuscule amount. But the revised proposal also adds a 100:1 ratio requirement that can make it more restrictive. For example, a 2-gram processed product containing 50 mg of mitragynine and 1 mg of 7-OH would meet July’s numerical thresholds but fail October’s ratio requirement, which permits only 0.5 mg in that example. Products that breach either restriction would face Schedule I control, so diluting a concentrated 7-OH product below the concentration ceiling would not save it if its ratio still fails. This 20 fold increase claim is wrong, and puts into question 60 Minutes' understanding of the Federal action.

According to FDA’s own presentation on concentrated synthetic 7-OH: “while some 7-OH products are marketed as natural kratom, they are not the same. Concentrated 7-OH presents significant risks.”

In October 2026, 7 of the leading kratom researchers published a peer reviewed paper giving robust policy guidelines - the outcome was clear, regulate natural kratom leaf, ban the dangerous concentrated synthetics causing the rise in adverse events.These 7 American leaders all agree with this approach.

Data In Context

Detection is not causation. CDC’s SUDORS data identify 5,208 kratom-involved — that is, mitragynine was detected — overdose deaths from 2020 through 2024. What this number leaves out is that detection is NOT causation. The CDC themselves warn that “determining which substance was most related to clinical effects or medical outcome, including death, was not possible.”

In the CDC’s review of 27,338 overdose deaths across 27 states (2016–2017), kratom was detected in 152 cases (0.56%). Fentanyl was detected in 99 of the 152 (65.1%) kratom detected deaths. Of those, CDC reported only 7 cases where kratom was the only substance detected, and explicitly cautioned that “the presence of additional substances could not be ruled out” due to incomplete or variable toxicology testing (Olsen et al., MMWR 2019).

Of 233 kratom-associated deaths reported to poison centers between 2015 and 2025, 79% involved multiple substances; opioids were reported in 62% of fatalities, followed by benzodiazepines, stimulants and alcohol. CDC expressly states that determining which substance was responsible for the outcome, including death, was not possible. Yet, 60 minutes has made that determination.

The cumulative number obscures the actual trend. As a percentage of total overdose deaths reported in SUDORS, kratom detection remained remarkably stable: 1.8% in 2020, 2.0% in 2021, 1.8% in 2022, 1.5% in 2023 and 1.9% in 2024. Kratom represented essentially the same share of overdose mortality in 2024 as it did in 2020. That data will change in 2025 and 2026 - why? Because of the introduction of dangerous synthetics like concentrated 7-OH, MGM 15 and MGPI. This is exactly why the DEA, HHS and FDA have moved to schedule these novel products.

A five-year cumulative count may sound alarming when taken out of context — and is presented in a way meant to sound alarming — but the underlying data show no sustained increase in natural kratom’s share of DETECTIONS in overdose deaths - detection is NOT causation. The annual average is roughly 1,042. For comparison, smoking and secondhand smoke account for more than 480,000 deaths a year, excessive alcohol use for 178,307, and opioid-involved overdose for 54,045.

The Attribution Problem

Poison control data and coroner reports typically do not specify kratom product type, incorrectly attributing consumer deaths to a centuries-old botanical. CDC acknowledges that its surveillance data cannot distinguish natural leaf from concentrated semisynthetic products, and has concluded that surveillance “should distinguish product types to assess risks.”

The consequences are documented. After the Los Angeles County Department of Public Health identified six fatal overdoses associated with concentrated synthetic 7-OH in September and October 2025, several California news organizations erroneously reported the deaths were caused by natural kratom leaf. As the scourge of lab-made opioids continues to spread, media outlets, law enforcement and public officials across the country are making the same mistake.

The exposure data tell the same story. Poison-center reports held flat for six years and then tripled in a single year — the year concentrated synthetic 7-OH products entered the market at scale. CDC states the increase “coincides with the emergence of high-potency, semisynthetic formulations, including 7-hydroxymitragynine” (Towers et al., MMWR 2026).

The Science Actually Shows

The broadcast told viewers that the body converts mitragynine into 7-OH, “eliciting an opioid high.” The available evidence strongly suggests that while a small portion of the mitragynine in natural leaf kratom converts in the body into natural 7-OH, it is nowhere near a 20% conversion rate. The conversion rate is between 1 and 5%. It occurs over an extended period of time, and its effects are mitigated by the plant’s other 50-plus alkaloids, fiber content, and antioxidants.

This conversion statement put forward by 60 minutes is intended to create a false equivalency. “Natrual kratom leaf is equivalent to concentrated synthetic 7-OH’ because mitragynine converts to 7-OH in the body’. The fact that the body converts some mitragynine into 7-OH does not establish that consuming natural leaf delivers an equivalent dose, produces the same effects, or carries the same risks. The broadcast presents a metabolic pathway as though it establishes product equivalence. It does not.

Kratom is a complex botanical with activity across multiple receptor systems. Its primary alkaloid, mitragynine, is a partial, low-efficacy agonist at the μ-opioid receptor and has a signaling profile distinct from classical full-agonist opioids. That difference matters: studies show mitragynine produces far less respiratory depression and evidence of a ceiling effect, unlike morphine, oxycodone and concentrated 7-OH.

Natural kratom leaf is not risk-free and should be regulated. But partial opioid-receptor activity does not make it pharmacologically equivalent to conventional opioid drugs. That erroneous claim, mistakes activity at the same receptor for pharmacological equivalence, ignoring the differences in dose, potency, efficacy, and metabolism that determine a substance’s effects and risks. This is basic pharmacology – 60 minutes has the obligation to get this right.

The Voices Silenced from the Conversation

60 Minutes did not include a single person whose life has improved thanks to natural kratom leaf. Federal officials did. When the FDA announced its action against concentrated synthetic 7-OH in July 2025, it invited chronic pain patient Melody Woolf to speak. “I was so grateful I found a botanical called kratom,” she said. “It was kratom only, the powdered leaf, that saved my life.”

Millions of Americans share her experience. Here are a few of them:

“I once considered ending my life, and then I found natural kratom. Natural kratom made life tolerable again. Protect access for people like me.” Dijon Evans, natural kratom leaf consumer
“I am a 63 year old wife and mother. Plain leaf kratom has given me back more than occasional pain relief. It has given me back my ability to think clearly, laugh, move, and enjoy my family. Before, my poor health consumed my thoughts and kept me confined to bed. Today, I can move with significantly less discomfort and even do advocacy work. Taking it away wouldn’t just take away a plant. It would take away my quality of life and my freedom.” Lesley Thomas, natural kratom leaf consumer
“The real problem is 7-OH, MGM and synthetic compounds, not medicinal kratom leaf powder. My fear too is with this ban people and I may turn to something that is actually harmful.” Matthew Johnson, 26, graduate student

The Natural Leaf Kratom Consumers Support

The Global Kratom Coalition supports access to natural kratom leaf, for adults 21 and over. That leaf should have independent testing, accurate labels, clear serving limits, and warnings about dependence and potential interactions. We also support targeted restrictions on concentrated synthetic 7-OH and related synthetic compounds.

The evidence shows a rapidly changing market and a genuine emerging problem with concentrated and synthetic products. It does not establish a growing poisoning or mortality crisis caused by natural kratom leaf.

About the Global Kratom Coalition

The Global Kratom Coalition is an alliance of natural kratom consumers, experts, and industry leaders dedicated to protecting access to natural kratom leaf while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit globalkratomcoalition.org.



Contact
Global Kratom Coalition
Info@globalkratomcoalition.org


Disclaimer. This is a paid press release.